1304 related articles for article (PubMed ID: 33917481)
1. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
[TBL] [Abstract][Full Text] [Related]
2. Properties of Coronavirus and SARS-CoV-2.
Malik YA
Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926
[TBL] [Abstract][Full Text] [Related]
3. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
5. Host Cell and SARS-CoV-2-Associated Molecular Structures and Factors as Potential Therapeutic Targets.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Roshan R; Azam F; Mehta J; Handu S; Prasad R; Jain N; Pandey AK; Dhamija P
Cells; 2021 Sep; 10(9):. PubMed ID: 34572076
[TBL] [Abstract][Full Text] [Related]
6. Potential drug targets of SARS-CoV-2: From genomics to therapeutics.
Shamsi A; Mohammad T; Anwar S; Amani S; Khan MS; Husain FM; Rehman MT; Islam A; Hassan MI
Int J Biol Macromol; 2021 Apr; 177():1-9. PubMed ID: 33577820
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
9. Precision therapeutic targets for COVID-19.
Krumm ZA; Lloyd GM; Francis CP; Nasif LH; Mitchell DA; Golde TE; Giasson BI; Xia Y
Virol J; 2021 Mar; 18(1):66. PubMed ID: 33781287
[TBL] [Abstract][Full Text] [Related]
10. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
Finkelstein MT; Mermelstein AG; Parker Miller E; Seth PC; Stancofski ED; Fera D
Viruses; 2021 Jan; 13(1):. PubMed ID: 33477902
[TBL] [Abstract][Full Text] [Related]
11. A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules.
Kumar D; Chauhan G; Kalra S; Kumar B; Gill MS
Bioorg Chem; 2020 Nov; 104():104326. PubMed ID: 33142431
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
Mohammed MEA
Curr Mol Med; 2022; 22(1):50-66. PubMed ID: 33622224
[TBL] [Abstract][Full Text] [Related]
13. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
14. Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19.
Rajarshi K; Khan R; Singh MK; Ranjan T; Ray S; Ray S
Gene; 2021 Feb; 768():145313. PubMed ID: 33220345
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
16. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Gupta VK; Murthy MK; Patil S
Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
[TBL] [Abstract][Full Text] [Related]
17. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
18. Long-chain polyphosphates impair SARS-CoV-2 infection and replication.
Ferrucci V; Kong DY; Asadzadeh F; Marrone L; Boccia A; Siciliano R; Criscuolo G; Anastasio C; Quarantelli F; Comegna M; Pisano I; Passariello M; Iacobucci I; Monica RD; Izzo B; Cerino P; Fusco G; Viscardi M; Brandi S; Pierri BM; Borriello G; Tiberio C; Atripaldi L; Bianchi M; Paolella G; Capoluongo E; Castaldo G; Chiariotti L; Monti M; De Lorenzo C; Yun KS; Pascarella S; Cheong JH; Kim HY; Zollo M
Sci Signal; 2021 Jul; 14(690):. PubMed ID: 34230209
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
